In conclusion, lixisenatide administered once daily as an add-on treatment to basal insulin with or without a sulfonylurea in Asian patients with type 2 diabetes and FPG at screening <250 mg/dl provided a significant improvement in HbA1c and a pronounced effect on postprandial glucose control. The gene discussed is INS; the disease is type 2 diabetes mellitus.